[go: up one dir, main page]

ITRM920693A1 - Impiego di l-carnitina e acil l-carnitine nel trattamento di pazienti affetti da aids e sindromi correlate e di pazienti asintomatici hivsieropositivi. - Google Patents

Impiego di l-carnitina e acil l-carnitine nel trattamento di pazienti affetti da aids e sindromi correlate e di pazienti asintomatici hivsieropositivi.

Info

Publication number
ITRM920693A1
ITRM920693A1 IT000693A ITRM920693A ITRM920693A1 IT RM920693 A1 ITRM920693 A1 IT RM920693A1 IT 000693 A IT000693 A IT 000693A IT RM920693 A ITRM920693 A IT RM920693A IT RM920693 A1 ITRM920693 A1 IT RM920693A1
Authority
IT
Italy
Prior art keywords
carnitine
patients
aids
related syndromes
acil
Prior art date
Application number
IT000693A
Other languages
English (en)
Inventor
Simone Claudio De
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Publication of ITRM920693A0 publication Critical patent/ITRM920693A0/it
Priority to ITRM920693A priority Critical patent/IT1258491B/it
Priority to ZA936300A priority patent/ZA936300B/xx
Priority to ES93114235T priority patent/ES2110551T3/es
Priority to EP93114235A priority patent/EP0590355B1/en
Priority to DE69315162T priority patent/DE69315162T2/de
Priority to AT93114235T priority patent/ATE160090T1/de
Priority to DK93114235.0T priority patent/DK0590355T3/da
Priority to KR1019930018520A priority patent/KR0136559B1/ko
Priority to JP5237790A priority patent/JPH06227983A/ja
Publication of ITRM920693A1 publication Critical patent/ITRM920693A1/it
Priority to US08/370,357 priority patent/US5631288A/en
Application granted granted Critical
Publication of IT1258491B publication Critical patent/IT1258491B/it
Priority to GR970402512T priority patent/GR3025372T3/el
Priority to HK98104022.7A priority patent/HK1004910B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ITRM920693A 1992-09-24 1992-09-24 Impiego di l-carnitina e acil l-carnitine nel trattamento di pazienti affetti da aids e sindromi correlate e di pazienti asintomatici hiv- sieropositivi. IT1258491B (it)

Priority Applications (12)

Application Number Priority Date Filing Date Title
ITRM920693A IT1258491B (it) 1992-09-24 1992-09-24 Impiego di l-carnitina e acil l-carnitine nel trattamento di pazienti affetti da aids e sindromi correlate e di pazienti asintomatici hiv- sieropositivi.
ZA936300A ZA936300B (en) 1992-09-24 1993-08-27 Use of L-carnitine and acyl L-carnitines for treating patients suffering from AIDS and AIDS-related syndromes and asymptomatic HIV-seropositive patients
DK93114235.0T DK0590355T3 (da) 1992-09-24 1993-09-06 Anvendelse af L-carnitin og acyl-L-carnitiner til behandling af patienter, der lider af AIDS-relaterede syndromer og asymptomatiske HIV-seropositive patienter
EP93114235A EP0590355B1 (en) 1992-09-24 1993-09-06 Use of L-carnitine and acyl L-carnitines for treating patients suffering from aids-related syndromes and asymptomatic HIV-seropositive patients
DE69315162T DE69315162T2 (de) 1992-09-24 1993-09-06 Verwendung von L-Carnitine und Acyl-L-Carnitinen zur Behandlung von Patienten die an AIDS-verwandten Syndromen leiden und von asymptomatischen HIV-seropositiven Patienten
AT93114235T ATE160090T1 (de) 1992-09-24 1993-09-06 Verwendung von l-carnitine und acyl-l-carnitinen zur behandlung von patienten die an aids- verwandten syndromen leiden und von asymptomatischen hiv-seropositiven patienten
ES93114235T ES2110551T3 (es) 1992-09-24 1993-09-06 Empleo de l-carnitina y acil l-carnitinas para tratamiento de pacientes que padecen sindromes relacionados con el sida y pacientes de hiv seropositivos asintomaticos.
KR1019930018520A KR0136559B1 (ko) 1992-09-24 1993-09-13 에이즈 및 에이즈 관련 증후군 환자 및 무증후성 hiv 혈청양성 환자 치료를 위한 l-카르니틴 및 아실 l-카르니틴의 용도
JP5237790A JPH06227983A (ja) 1992-09-24 1993-09-24 エイズ治療のためのｌ−カルニチン類の使用
US08/370,357 US5631288A (en) 1992-09-24 1995-01-09 Therapeutic method of treating patients suffering from AIDS and AIDS-related syndromes and asymptomatic HIV-seropositive patients.
GR970402512T GR3025372T3 (en) 1992-09-24 1997-11-13 Use of l-carnitine and acyl l-carnitines for treating patients suffering from aids-related syndromes and asymptomatic hiv-seropositive patients
HK98104022.7A HK1004910B (en) 1992-09-24 1998-05-09 Use of l-carnitine and acyl l-carnitines for treating patients suffering from aids-related syndromes and asymptomatic hiv-seropositive patients

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITRM920693A IT1258491B (it) 1992-09-24 1992-09-24 Impiego di l-carnitina e acil l-carnitine nel trattamento di pazienti affetti da aids e sindromi correlate e di pazienti asintomatici hiv- sieropositivi.

Publications (3)

Publication Number Publication Date
ITRM920693A0 ITRM920693A0 (it) 1992-09-24
ITRM920693A1 true ITRM920693A1 (it) 1994-03-24
IT1258491B IT1258491B (it) 1996-02-26

Family

ID=11401203

Family Applications (1)

Application Number Title Priority Date Filing Date
ITRM920693A IT1258491B (it) 1992-09-24 1992-09-24 Impiego di l-carnitina e acil l-carnitine nel trattamento di pazienti affetti da aids e sindromi correlate e di pazienti asintomatici hiv- sieropositivi.

Country Status (11)

Country Link
US (1) US5631288A (it)
EP (1) EP0590355B1 (it)
JP (1) JPH06227983A (it)
KR (1) KR0136559B1 (it)
AT (1) ATE160090T1 (it)
DE (1) DE69315162T2 (it)
DK (1) DK0590355T3 (it)
ES (1) ES2110551T3 (it)
GR (1) GR3025372T3 (it)
IT (1) IT1258491B (it)
ZA (1) ZA936300B (it)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6922994A (en) * 1993-06-21 1995-01-17 Bernardini, Attilio Use of acylcarnitin to treat illnesses caused by aids
IT1291113B1 (it) * 1997-03-20 1998-12-29 Sigma Tau Ind Farmaceuti Composizione nutritiva terapeutica per soggetti affetti da diabete mellito
IT1291127B1 (it) * 1997-04-01 1998-12-29 Sigma Tau Ind Farmaceuti Integratore alimentare per soggetti dediti ad intensa e prolungata attivita' fisica
US6503506B1 (en) * 2001-08-10 2003-01-07 Millenium Biotechnologies, Inc. Nutrient therapy for immuno-compromised patients
US20050232911A1 (en) * 2004-04-19 2005-10-20 Schreiber Brian D Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid
US20080119386A1 (en) * 2006-11-22 2008-05-22 Carl Germano Nutritional formula for athletes' recovery
PL3050568T3 (pl) 2007-03-13 2021-06-14 Jds Therapeutics, Llc Sposoby i kompozycje do przedłużonego uwalniania chromu
WO2009002867A2 (en) 2007-06-26 2008-12-31 Nutrition 21, Inc. Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
MX2018009748A (es) 2016-02-11 2019-02-07 Nutrition 21 Llc Composiciones que contienen cromo para mejorar la salud y el estado físico.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1143214B (it) * 1981-07-09 1986-10-22 Sigma Tau Ind Farmaceuti Acil derivato della carnitina quale immunomodulatore
IT1157238B (it) * 1982-10-29 1987-02-11 Sigma Tau Ind Farmaceuti Impiego di 1-carnitina per migliorare i paramenti biochimici e comportamentali dell'eta' senile
US5272153A (en) * 1986-12-31 1993-12-21 Hoechst-Roussel Pharmaceuticals, Inc. Method of inhibiting the activity of leukocyte derived cytokines
US4968719A (en) * 1989-04-03 1990-11-06 Sigma Tau, Industrie Farmaceutiche Riunite Spa Method for treating vascular disease

Also Published As

Publication number Publication date
ATE160090T1 (de) 1997-11-15
US5631288A (en) 1997-05-20
DE69315162T2 (de) 1998-03-12
ES2110551T3 (es) 1998-02-16
EP0590355B1 (en) 1997-11-12
ZA936300B (en) 1995-02-27
GR3025372T3 (en) 1998-02-27
DK0590355T3 (da) 1998-03-02
HK1004910A1 (en) 1998-12-11
JPH06227983A (ja) 1994-08-16
ITRM920693A0 (it) 1992-09-24
DE69315162D1 (de) 1997-12-18
IT1258491B (it) 1996-02-26
KR940006576A (ko) 1994-04-25
EP0590355A1 (en) 1994-04-06
KR0136559B1 (ko) 1998-04-25

Similar Documents

Publication Publication Date Title
DK0600079T3 (da) Oral 1alpha-hydroxyprævitamin D
ES2086270T5 (es) Metabolitos de terfenadina y sus isomeros opticamente puros para tratar trastornos alergicos.
MX9203543A (es) Medicamento.
IT8620298A0 (it) Sali di diacetilreina e loro impiego terapeutico nel trattamento dell'artrosi.
GB2285219B (en) Use of norastemizole for the treatment of allergic disorders
ATE99172T1 (de) Verwendung von acetyl-l-carnitin zur behandlung von katarakt, sowie pharmazeutische zusammensetzungen fuer eine derartige behandlung.
DK0629400T3 (da) Idebenon-holdige præparater til behandling af Alzheimer's syge
ITRM920693A1 (it) Impiego di l-carnitina e acil l-carnitine nel trattamento di pazienti affetti da aids e sindromi correlate e di pazienti asintomatici hivsieropositivi.
ATE135909T1 (de) Verfahren zur behandlung von akne
ES2026304A6 (es) Procedimiento de fabricacion de una forma de dosificacion de nicardipina.
DK0498144T3 (da) Anvendelse af acetyl-L-carnitin ved terapeutisk behandling af coma
LU90791I2 (fr) Potentialisateur d'effets antineoplasique et agent antineoplasique
KR910015300A (ko) 부스피론 : 수면 무호흡증의 치료용도
AU670491C (en) Pharmaceutical for the treatment of skin disorders
ATE229981T1 (de) Glykolisierte cytokine
EP0642338A1 (en) USE OF (E) - 2 - (P -FLUOROPHENETHYL) - 3 - FLUOROALLYLAMINE FOR TREATING ALZHEIMER'S DISEASE.
ATE70977T1 (de) Medikamente fuer die behandlung von rheumatoider arthritis.
ATE79750T1 (de) Pharmazeutische zusammensetzung mit antikrebswirkung und methode fuer die behandlung von krebs.
FI930097A7 (fi) Annostusmuoto lääkeaineen antamiseksi vuorokausiterapian toteuttamista varten
KR930019207A (ko) 카르니틴 결핍 hiv-혈청양성 환자 치료용 l-카르니틴의 용도
RU93044256A (ru) Способ лечения саркоидоза
UA15281A (uk) Спосіб лікуваhhя хроhічhої ішемічhої хвороби серця
RU93027571A (ru) Способ усиления противоопухолевого эффекта лучевой терапии

Legal Events

Date Code Title Description
0001 Granted
TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19970709